Biogena Group Invest’s €20 Million Subscription Race Nears Finish Line Ahead of Key Earnings Date

Shares surge 59% YTD after parent Biogena Good Vibes AG launches €20–25M capital raise for expansion, including e-commerce and longevity solutions, ahead of Vision 2030.

Shares of Biogena Group Invest AG pushed to a fresh 52-week high of €4.80 this week before settling at €4.70 on Friday, a 3.52% gain that takes the year-to-date advance to 59.27%. The rally comes as the clock winds down on a critical fundraising effort by the group’s parent holding company, Biogena Good Vibes AG, which has been offering new common shares at €4.803 apiece since mid-June. The subscription period, set to expire on 22 July 2026 but subject to extension or early closure, is targeting €20 million – and up to €25 million if the over-allotment option is fully taken up.

Proceeds from the capital increase are earmarked for a series of growth initiatives that map directly onto the group’s broader strategic ambitions. Biogena plans to expand its “Good Health World” campus in Koppl, near Salzburg, develop its “World of Biogena” e-commerce platform, roll out PLAZA retail concepts in Austria and Germany, invest in wellbeing diagnostics and longevity solutions, and ramp up production capacity for its Biogena ONE line. The company also intends to strengthen its online marketing in Germany, a market where it sees significant untapped potential.

These investments are underpinned by a clear revenue trajectory. Management’s “Vision 2030” targets group sales of €500 million by the end of the decade, a sharp step-up from the €124.9 million recorded in the 2024/2025 financial year. For the current fiscal period, the company is guiding for roughly €150 million – a jump that would validate the intermediate growth path toward the half-billion mark. The operating business, supported by a network of more than 480 employees and around 30,000 partner physicians and therapists, counts over one million customers across more than 70 countries.

The capital raise sits within a broader corporate restructuring that has drawn intense interest from investors. Earlier this year, founder Albert Schmidbauer signalled an intended valuation of around €475 million for the Biogena Good Vibes AG holding entity as part of a planned IPO process. That figure, while distinct from the much smaller €18.27 million market capitalisation of the listed Biogena Group Invest AG, reflects the entwined nature of the two vehicles: Group Invest AG holds a 3.869% stake in the operating KG, through which investors gain indirect exposure to the group’s underlying business.

Looking ahead, shareholders have two dates circled on their calendars. The half-year results for Biogena Group Invest are scheduled for release on 27 August 2026, which will offer the first detailed look at whether the rapid revenue acceleration is on track. Meanwhile, the Good Vibes AG is exploring a further capital increase, potentially as early as June 2026, that could restructure the group’s holding architecture and strengthen the parent company’s role as the primary capital-markets vehicle. No binding decision has been taken, and details on timing, terms or exchange ratios remain provisional.

Technically, the stock is showing clear momentum. Friday’s close of €4.70 sits roughly 49% above its 200-day moving average, while the relative strength index at 63.4 points to strong but not overbought buying pressure. With the subscription deadline looming and the half-year report on the horizon, the convergence of fundraising, growth targets and structural overhaul is keeping Biogena Group Invest firmly in the spotlight.